A Phase 2 interventional study of Bimekizumab in Ankylosing Spondylitis, sponsored by UCB Biopharma SRL. Completed at 50 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-21.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Spondylitis, Ankylosing by UCB S.A. — none open to participants now, none under way, none of them phase 3. Spondylitis, Ankylosing · UCB S.A..
Among the 11 studies in Spondylitis, Ankylosing by UCB S.A., this one is one of 2 that started in 2017, is one of 3 in phase 2, and was the 9th registered.
533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.
Browse Spondylitis, Ankylosing studies →None of the 11 studies in Spondylitis, Ankylosing by UCB S.A. is open now. The open studies under Spondylitis, Ankylosing, anywhere →
Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 255 is above the median of 88 across 303 interventional studies indexed under Spondylitis, Ankylosing.
Median enrollment 303 across the 9 interventional studies, 341 across the 2 observational. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Spondylitis, Ankylosing by UCB S.A., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a study to assess the long term safety and tolerability of bimekizumab in subjects with ankylosing spondylitis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive bimekizumab up to 4 years.
Drug: Bimekizumab
Bimekizumab at a prespecified dose.
Also known as: UCB4940
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study
An Adverse Event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Treatment emergent adverse events were defined as those events with onset date on or after the first administration of study medication in AS0009 and on or before 140 days after the final study medication administration.
Time frame: From Entry Visit (Visit 1) until Safety Follow Up (up to Week 224)
Percentage of Participants With Serious Adverse Event (SAE) During the Study
A serious adverse event (SAE) is any untoward medical occurrence that at any dose: 1) Results in death 2) Is life-threatening 3) Requires in participant hospitalisation or prolongation of existing hospitalisation 4) Is a congenital anomaly or birth defect 5) Is an infection that requires treatment with parenteral antibiotics 6) Other important medical events which based on medical or scientific judgement may jeopardise the participants, or may require medical or surgical intervention to prevent any of the above.
Time frame: From Entry Visit (Visit 1) until Safety Follow Up (up to Week 224)
Percentage of Participants Who Withdrew Due to an Treatment-emergent Adverse Event (TEAE) During the Study
An Adverse Event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Treatment emergent adverse events were defined as those events with onset date on or after the first administration of study medication in AS0009 and on or before 140 days after the final study medication administration.
Time frame: From Entry Visit (Visit 1) until Safety Follow Up (up to Week 224)
Percentage of Participants With Axial Spondyloarthritis International Society 40% Response Criteria (ASAS40) at Week 48 Calculated Relative to Baseline of AS0008
The ASAS40 response was defined as relative improvements of at least 40% and absolute improvement of at least 2 units on a 0 to 10 Numeric Rating Scale (NRS), where 0 is "not active" and 10 is "very active" in at least 3 of the 4 domains: Patient's Global Assessment of Disease Activity (PGADA) (score ranged from 0 (not active) to 10 (very active), Pain assessment (total spinal pain NRS score) (assessed on a scale of 0 (no pain) to 10 (severe pain)), Function (Bath Ankylosing Spondylitis Functional Index (BASFI)) (score ranged from 0 (easy) to 10 (impossible)), Inflammation (mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) questions 5 and 6 concerning morning stiffness intensity and duration) (score ranged from 0 (none) to 10 (very severe) and no worsening at all in the remaining domain. Participants for whom ASAS could not be derived due to missing data were counted as non-responders.
Time frame: Baseline of AS0008, Week 48 (AS0009)
Percentage of Participants With Axial Spondyloarthritis International Society 20% Response Criteria (ASAS20) at Week 48 Calculated Relative to Baseline of AS0008
The ASAS20 response was defined as relative improvements of at least 20% and absolute improvement of at least 1 unit on a 0 to 10 NRS, where 0 is "not active" and 10 is "very active" in at least 3 of the 4 domains: PGADA (score ranged from 0 (not active) to 10 (very active), Pain assessment (total spinal pain NRS score) (assessed on a scale of 0 (no pain) to 10 (severe pain)), Function (BASFI) (score ranged from 0 (easy) to 10 (impossible)), Inflammation (mean of BASDAI) questions 5 and 6 concerning morning stiffness intensity and duration) (score ranged from 0 (none) to 10 (very severe) and no worsening at all in the remaining domain. Participants for whom ASAS could not be derived due to missing data were counted as non-responders.
Time frame: Baseline of AS0008, Week 48 (AS0009)
Change From Baseline of AS0008 in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score to Week 48
BASDAI is a validated self-reported instrument, which consisted of 6 questions to measure the disease activity of ankylosing spondylitis (AS) from the participant's perspective. It measured the severity of fatigue, spinal and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and duration). Each question was rated using a numerical rating scale from 0 (none) to 10 (very severe), higher score=high disease activity. The BASDAI score was calculated by computing the mean of questions 5 and 6 and adding it to the sum of questions 1 to 4. This score was then divided by 5. The total BASDAI score was ranged from 0=none to 10= very severe, where higher score indicated high disease activity. A negative value indicated improvement and a positive value indicated worsening.
Time frame: Baseline of AS0008, Week 48 (AS0009)
The study started to enroll study participants in November 2017 and concluded in October 2022. Participants who completed AS0008 (NCT02963506) participated in this study.
| Milestone | Bimekizumab |
|---|---|
| Started | 255 |
| Completed | 202 |
| Not completed | 53 |
| Withdrew: Withdrew consent due to refused treatment to ae latent tuberculosis | 1 |
| Withdrew: Sponsor's decision | 1 |
| Withdrew: Participant withdrew consent due to aes | 1 |
| Withdrew: Pi's decision | 2 |
| Withdrew: Withdrawal by subject | 23 |
| Withdrew: Lost to follow-up | 4 |
| Withdrew: Lack of efficacy | 2 |
| Withdrew: Adverse event, non-fatal | 17 |
| Withdrew: Adverse event, serious fatal | 2 |
An Adverse Event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Treatment emergent adverse events were defined as those events with onset date on or after the first administration of study medication in AS0009 and on or before 140 days after the final study medication administration.
| percentage of participants | Bimekizumab |
|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study | 92.9 |
A serious adverse event (SAE) is any untoward medical occurrence that at any dose: 1) Results in death 2) Is life-threatening 3) Requires in participant hospitalisation or prolongation of existing hospitalisation 4) Is a congenital anomaly or birth defect 5) Is an infection that requires treatment with parenteral antibiotics 6) Other important medical events which based on medical or scientific judgement may jeopardise the participants, or may require medical or surgical intervention to prevent any of the above.
| percentage of participants | Bimekizumab |
|---|---|
| Percentage of Participants With Serious Adverse Event (SAE) During the Study | 18.0 |
An Adverse Event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Treatment emergent adverse events were defined as those events with onset date on or after the first administration of study medication in AS0009 and on or before 140 days after the final study medication administration.
| percentage of participants | Bimekizumab |
|---|---|
| Percentage of Participants Who Withdrew Due to an Treatment-emergent Adverse Event (TEAE) During the Study | 6.7 |
The ASAS40 response was defined as relative improvements of at least 40% and absolute improvement of at least 2 units on a 0 to 10 Numeric Rating Scale (NRS), where 0 is "not active" and 10 is "very active" in at least 3 of the 4 domains: Patient's Global Assessment of Disease Activity (PGADA) (score ranged from 0 (not active) to 10 (very active), Pain assessment (total spinal pain NRS score) (assessed on a scale of 0 (no pain) to 10 (severe pain)), Function (Bath Ankylosing Spondylitis Functional Index (BASFI)) (score ranged from 0 (easy) to 10 (impossible)), Inflammation (mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) questions 5 and 6 concerning morning stiffness intensity and duration) (score ranged from 0 (none) to 10 (very severe) and no worsening at all in the remaining domain. Participants for whom ASAS could not be derived due to missing data were counted as non-responders.
| percentage of participants | Bimekizumab |
|---|---|
| Non-responder imputation | 67.1 |
| Observed case | 70.5 |
The ASAS20 response was defined as relative improvements of at least 20% and absolute improvement of at least 1 unit on a 0 to 10 NRS, where 0 is "not active" and 10 is "very active" in at least 3 of the 4 domains: PGADA (score ranged from 0 (not active) to 10 (very active), Pain assessment (total spinal pain NRS score) (assessed on a scale of 0 (no pain) to 10 (severe pain)), Function (BASFI) (score ranged from 0 (easy) to 10 (impossible)), Inflammation (mean of BASDAI) questions 5 and 6 concerning morning stiffness intensity and duration) (score ranged from 0 (none) to 10 (very severe) and no worsening at all in the remaining domain. Participants for whom ASAS could not be derived due to missing data were counted as non-responders.
| percentage of participants | Bimekizumab |
|---|---|
| Non-responder imputation | 79.9 |
| Observed case | 84.0 |
BASDAI is a validated self-reported instrument, which consisted of 6 questions to measure the disease activity of ankylosing spondylitis (AS) from the participant's perspective. It measured the severity of fatigue, spinal and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and duration). Each question was rated using a numerical rating scale from 0 (none) to 10 (very severe), higher score=high disease activity. The BASDAI score was calculated by computing the mean of questions 5 and 6 and adding it to the sum of questions 1 to 4. This score was then divided by 5. The total BASDAI score was ranged from 0=none to 10= very severe, where higher score indicated high disease activity. A negative value indicated improvement and a positive value indicated worsening.
| scores on a scale | Bimekizumab |
|---|---|
| Change From Baseline of AS0008 in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score to Week 48 | -3.79 ± 0.13 |
Collected over From Entry Visit (Visit 1) until Safety Follow Up (up to Week 224). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bimekizumab | 2/255 (0.8%) | 46/255 (18%) | 176/255 (69%) |
| Event | Bimekizumab |
|---|---|
| PneumoniaInfections and infestations | 3/255 |
| Corona virus infectionInfections and infestations | 3/255 |
| Colitis ulcerativeGastrointestinal disorders | 2/255 |
| Perirectal abscessInfections and infestations | 2/255 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/255 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 2/255 |
| Coronary artery diseaseCardiac disorders | 1/255 |
| Coronary artery stenosisCardiac disorders | 1/255 |
| Cardiac failureCardiac disorders | 1/255 |
| Cardio-respiratory arrestCardiac disorders | 1/255 |
| Event | Bimekizumab |
|---|---|
| NasopharyngitisInfections and infestations | 46/255 |
| Upper respiratory tract infectionInfections and infestations | 33/255 |
| Corona virus infectionInfections and infestations | 30/255 |
| BronchitisInfections and infestations | 21/255 |
| Alanine aminotransferase increasedInvestigations | 19/255 |
| PharyngitisInfections and infestations | 18/255 |
| Oral candidiasisInfections and infestations | 17/255 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 16/255 |
| SinusitisInfections and infestations | 15/255 |
| TonsillitisInfections and infestations | 15/255 |
Baseline Characteristics refer to the Safety Set consisted of all participants in the enrolled set who received at least one dose of study medication in AS0009.
| Age, Categorical(Participants) | Bimekizumab |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 245 |
| >=65 years | 10 |
| Age, Continuous(years) | Bimekizumab |
|---|---|
| Mean | 41.8 ± 11.4 |
| Sex: Female, Male(Participants) | Bimekizumab |
|---|---|
| Female | 38 |
| Male | 217 |
| Race/Ethnicity, Customized(Participants) | Bimekizumab |
|---|---|
| White | 253 |
| Other/Mixed | 2 |
| Race/Ethnicity, Customized(Participants) | Bimekizumab |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 254 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2017 to primary completion in Oct 2022, 58 months.
Results were first posted in Nov 2024, 2 years after primary completion. A results delay was requested in Oct 2023.
Of 22 phase 2 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 58 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimekizumab